Source: International Congress 2016 – IPF treatment II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Elisabetta Balestro (Padova, Italy), Elisabetta Balestro, Graziella Turato, Davide Biondini, Sofia Pavanello, Alessia Fraccaro, Chiara Rigobello, Erica Bazzan, Manuela Campisi, Simonetta Baraldo, Manuel Cosio, Marina Saetta, Paolo Spagnolo. Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2016; 48: Suppl. 60, 4965

Member's Comments

No comment yet.

Related content which might interest you: Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013